In a large collaborative study combining three separate whole-genome association studies, the CAC-NA1C gene (rs1006737) was recently found to display a genome-wide significant association with bipolar disorder (BPD). Here, we report for the first time the ND, not determined. Subjects were matched for age (schizophrenia (S)1 (serum) = 25 ± 7 years; S2 (plasma) = 23 ± 4 years; S3 (plasma) = 34 ± 12 years; S4 (serum) = 30±7 years; bipolar disorder (BD) (serum) = 37 ± 11 years) and body mass index (24 ± 5 kg m À2 across all cohorts). Cohorts were comprised (male/female) of the following: S1-controls (cont) = 12/5, schiz = 10/0; S2-cont = 21/0, schiz = 26/0; S3-cont = 6/4, schiz = 7/3; S4-cont = 9/11, schiz = 10/10; BD-cont = 5/5; BD = 5/5. Glucose was determined using the Dimension RXL system (Dade Behring, Dallas, TX, USA) (control levels = 4.6±0.8 mM). Insulin was determined using a two-step time-resolved fluorometric (TRF) assay 9 (control levels = 75.1 ± 58.6 pM). Proinsulin and des31,32-proinsulin were determined using two-site TRF assays 7 (control levels = 4.9±4.4 and 5.9±5.2 pM, respectively). C-peptide was measured using the Immulite system (DPC Diagnostic Products Corp, Los Angeles, CA, USA) (control levels = 1.9±1.3 nM). Chromogranin A was measured using a two-site immunoassay kit (ALPCO Diagnostics, Salem, NH, USA) (control levels = 29.6 ± 21.3 ng ml
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). Fold change (FC) was calculated as the disease:control ratio of analyte levels. Statistical significance (P-value) was determined by two-tailed t-tests. Significant FC values are indicated in bold font. significant association of the same SNP with schizophrenia (SZ), with the same risk allele and odds ratio as observed for BPD.
Sklar et al. 1 reported the association between CACNA1C and BPD for rs1006737 (P-value = 3.15 Â 10
À6
) in a combined analysis of two genome-wide association studies (WTCCC and STEP-UCL dataset). Further evidence of the involvement of rs1006737 in BPD was found combining the WTCCC/STEP-UCL sample with a third genome-wide association study (ED-DUB-STEP2) (P = 7.0 Â 10 -8 ). 2 The involvement of CACNA1C in BPD is therefore established with a high degree of certainty due to rs1006737 passing genomewide significance. Accumulating evidence suggests that BPD and SZ have some genetic risk factors in common. 3, 4 These results motivated us to test rs1006737 for association with SZ in a sample of 986 patients and 1501 control individuals collected in three Danish studies. All the studies were approved by the Danish Data Protection Agency and by the ethics committees in Denmark.
Denmark I: This sample included 385 SZ patients and 780 controls matched on the basis of gender and date of birth. The patients were recruited to the Danish Psychiatric Biobank and diagnosed with SZ according to the ICD-10 criteria. The control individuals were ethnically Danish blood donors.
Denmark II: This sample consisted of 366 SZ patients recruited from the Danish Newborn Screening Biobank. 5 The patients, all born in Denmark, were diagnosed with SZ according to ICD-10 criteria. The patients are matched on the basis of gender and date of birth to at least one control individual from the Biobank. In total, 435 controls with no record of mental illness were included.
Denmark III: This sample included 235 incident SZ patients and 286 medical student volunteers as controls. The patients were diagnosed according to ICD-10-DCR using SCAN interviews and a best estimate procedure. The patients and controls were of Danish parentage for three generations.
Genotyping of individuals from the studies Denmark I and III was performed using genomic DNA isolated from blood samples. Individuals from the Denmark II study were genotyped using whole genome-amplified DNA from neonatal dried blood spot samples. 6 Rs1006737 was genotyped using the Sequenom MassARRAY System (Sequenom, San Diego, CA, USA) (primer sequences available on request). Call rate was 0.991, and no deviation from Hardy-Weinberg Equilibrium was observed among patients (P = 0.677) or controls (P = 0.448). A total of 22 individuals (10 patients and 12 controls) were removed from the analysis due to failed genotyping. A stratified association analysis was performed using the Cochran-Mantel-Haenszel test in the open-source software PLINK (http://pngu.mgh.harvard.edu/~pur-cell/plink/). 7 For the Denmark I and Denmark II samples, each patient and their matched control(s) were treated as one cluster. The unmatched patients and controls from the Denmark III sample were analyzed as a single cluster. Significant association was found between rs1006737 and SZ: odds ratio (OR) = 1.16 and P = 0.015 (Table 1) .
In our combined Danish sample, the odds ratio and risk allele frequency of rs1006737 for SZ were similar to the results reported for BPD in the WTCCC/ STEP-UCL/ED-DUB-STEP2 study 2 (Table 1) . Thus, our finding suggests that CACNA1C is a common risk gene for both BPD and SZ. However, replication analyses in both BPD and SZ are warranted.
It is unknown whether rs1006737 is the causal variant or whether the association is caused by a yet unidentified variant in linkage disequilibrium with rs1006737. In the Hapmap CEU data, the intronic rs1006737 shows complete linkage disequilibrium (r 2 = 1), with five SNPs also positioned in the third intron of CACNA1C. Although rs1006737 may be used as a predictive marker, identification of the true susceptibility variant remains challenging and will involve replication, re-sequencing and functional studies.
CACNA1C encodes the a 1C subunit (Cav 1.2) of the L-type voltage-dependent calcium channel. Calcium influx through such channels is coupled to signaling pathways that stimulate the expression of genes essential for neuronal survival and plasticity, 8 and rare mutations in CACNA1C are known to cause cognitive abnormalities and autism. 9 The association 
